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RhoAIn response to stress or injury the heart undergoes an adverse remodeling process associatedwith cardiomyocyte
hypertrophy and ﬁbrosis. Transformation of cardiac ﬁbroblasts to myoﬁbroblasts is a crucial event initiating the
ﬁbrotic process. Cardiac myoﬁbroblasts invade themyocardium and secrete excess amounts of extracellular ma-
trix proteins, which causemyocardial stiffening, cardiac dysfunctions and progression to heart failure.While sev-
eral studies indicate that the small GTPase RhoA can promote proﬁbrotic responses, the exchange factors that
modulate its activity in cardiac ﬁbroblasts are yet to be identiﬁed. In the present study, we show that AKAP-
Lbc, an A-kinase anchoring protein (AKAP) with an intrinsic Rho-speciﬁc guanine nucleotide exchange factor
(GEF) activity, is critical for activating RhoA and transducing proﬁbrotic signals downstreamof type I angiotensin
II receptors (AT1Rs) in cardiac ﬁbroblasts. In particular, our results indicate that suppression of AKAP-Lbc expres-
sion by infecting adult rat ventricular ﬁbroblasts with lentiviruses encoding AKAP-Lbc speciﬁc short hairpin (sh)
RNAs strongly reduces the ability of angiotensin II to promote RhoA activation, differentiation of cardiac ﬁbro-
blasts to myoﬁbroblasts, collagen deposition as well as myoﬁbroblast migration. Interestingly, AT1Rs promote
AKAP-Lbc activation via a pathway that requires the α subunit of the heterotrimeric G protein G12. These ﬁnd-
ings identify AKAP-Lbc as a key Rho-guanine nucleotide exchange factormodulating proﬁbrotic responses in car-
diac ﬁbroblasts.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiac ﬁbroblasts constitute the predominant cell population in the
myocardium and play a key role in maintaining the structural integrity
of the heart through controlled proliferation and extracellular matrix
(ECM) turnover [1,2]. In response to a neurohumoral or biomechanical
stress placed on the heart, quiescent cardiac ﬁbroblasts undergo a phe-
notypic transition to proﬁbrogenicmyoﬁbroblasts, which are character-
ized by the expression of α-smooth muscle actin (α-SMA) [1,2], a
contractile protein normally associated with smooth muscle cells.
Myoﬁbroblasts display a more mobile phenotype [3] and possess a
greater synthetic ability to produce collagen-rich ECM proteins
and proﬁbrotic cytokines including the transforming growth factor β
(TGF-β) [4]. Over the time, excessive formation of ﬁbrous connective
tissue and ECM leads to cardiac ﬁbrosis. This impairs electrical coupling-kinase anchoring protein; GEF,
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ights reserved.between cardiomyocytes and increases myocardial stiffness, leading ar-
rhythmias and severe diastolic dysfunctions. The key role of cardiac ﬁ-
broblast in the cardiac remodeling process associated with cardiac
hypertrophy and heart failure makes them an attractive target for the
treatment of heart failure [1].
Among the factors produced in the remodeling heart that affect the
phenotype and function of cardiac ﬁbroblasts, angiotensin II (Ang II)
has been shown to contribute importantly to the development of cardi-
ac ﬁbrosis [1,3]. In this respect, several studies indicate that the
proﬁbrotic actions of Ang II aremainlymediated by the type 1 angioten-
sin II receptor (AT1R), a G protein coupled receptor linked to the
heterotrimeric G proteins Gq andG12/13 [5]. By promotingmyoﬁbroblast
transdifferentiation, activated AT1Rs favor ECM accumulation and
TGFβ-1 synthesis, and, as a consequence, ﬁbrosis [3,6].
Several lines of evidence now suggest that the small molecular
weight GTPase RhoA plays a crucial role inmediating several proﬁbrotic
responses in cardiac ﬁbroblasts [7–10]. In this respect, recent ﬁndings
indicate that RhoA can promoteα-SMA expression in cardiacﬁbroblasts
through a signaling pathway that involves actin polymerization and the
nuclear translocation of myocardin related transcription factors
(MRTFs) [9,10]. Moreover, exposure of cardiac myoﬁbroblasts to an in-
hibitor of Rho-kinase, a downstreameffector of RhoA, inhibits cardiacﬁ-
broblast migration [11]. Finally, disruption of the gene encoding the
Rho-kinase ROCK1 reduces collagen deposition and prevents reactive
cardiac ﬁbrosis induced by Ang II infusion or pressure overload [12,13].
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bound and inactive GDP-bound states. In vivo, the cycling between the
GDP- and GTP-bound forms is regulated by guanine nucleotide-
exchange factors (GEFs) that stimulate the exchange of GDP with GTP.
We have previously identiﬁed an exchange factor mainly expressed
in the heart, termed AKAP-Lbc, which functions as GEF for RhoA
(Rho-GEF) as well as an A-kinase anchoring protein (AKAP) [14]. In
cardiomyocytes, the Rho-GEF activity of AKAP-Lbc Rho-GEF is enhanced
in response to the activation of α1-adrenergic receptors (ARs) through
a signaling pathway that requires the α subunit of the heterotrimeric G
protein G12 [14,15]. Silencing AKAP-Lbc expression in rat neonatal ven-
tricular myocytes (NVMs) strongly inhibits the ability of α1-ARs to in-
duce RhoA activation and hypertrophic responses, suggesting a role
for this anchoring protein in cardiac remodeling [15,16].
While the implication of RhoA signaling in cardiac ﬁbrosis has been
proposed by several studies, the identity of the Rho-GEFs that trans-
duces ﬁbrotic signals in cardiac ﬁbroblasts has remained elusive. In
the present study, we used a lentivirus-based strategy to deliver
AKAP-Lbc-speciﬁc short hairpin (sh) RNAs into primary cultures of rat
adult ventricular ﬁbroblasts (AVFs) or myoﬁbroblasts (AVMyoFs).
Using this approach, we could demonstrate that AKAP-Lbc plays a key
role in mediating Ang II-induced ﬁbrotic responses. In particular, we
found that AKAP-Lbc participates in a signaling cascade activated by
AT1Rs that includes Gα12, AKAP-Lbc, and RhoA. This pathway promotes
α-SMA expression and myoﬁbroblast differentiation and associated in-
creased TGF-β1 production, collagen deposition as well as myoﬁbroblast
motility. Collectively, these ﬁndings identify AKAP-Lbc as the ﬁrst Rho-
GEF regulating proﬁbrotic signals in cardiac ﬁbroblasts.2. Material and methods
2.1. Expression constructs
Double-stranded hairpin oligonucleotides based upon rat AKAP-Lbc
mRNA sequences (GI: 198386327, bases 6347–6365 and 6626–6644)
were cloned into the HindIII and BglII sites in the pSUPER vector. The
following oligonucleotide sequences were used: AKAP-Lbc shRNA1
(sense strand) 5′-GCAAGTCGATCATGAGAAT-3′; AKAP-Lbc shRNA2
(sense strand) 5′-GGATAAGCGTTTCCAAGCC-3′; mutated AKAP-Lbc
shRNA (sense strand) 5′-GCATGTCGATCATGCGATT-3′. Underlined
base pairs in the mutated shRNA differ from the wild-type AKAP-Lbc
shRNA. To generate lentiviral transfer vectors encoding AKAP-Lbc
shRNAs, cDNA fragments containing theH1RNApolymerase III promot-
er as well as the sequences encoding shRNAs were excised using
BamHI/SalI from the pSUPER vector and subcloned into the pAB286.1
transfer vector. To generate the Gα12 G228A-pAB286.1 vector, a
BamHI/XhoI fragment containing the CMV promoter and the entire
open reading frame for the Gα12 G228A mutant was PCR-ampliﬁed
from the Gα12 G228A-pCDNA3.1 vector and subcloned into the BamHI
and SalI sites in the pAB286.1 vector. To generate the RhoA N19-
pAB286.1 vector, a BamHI/SalI fragment containing the CMV promoter
and the entire open reading frame for the RhoA N19 mutant was PCR-
ampliﬁed from the RhoA N19-pFLAG-CMV-6c vector and subcloned
into the BamHI and SalI sites in the pAB286.1 vector. The lentiviral pack-
aging vectors pCMVDR8.91 and pMD2.VSVG encode the viral capsid and
the vesicular stomatitis virus-G envelope protein, respectively. Plasmids
encoding GFP fusions of AKAP-Lbc and AKAP-Lbc Y2153F were de-
scribed previously [14].2.2. Peptide synthesis
Arg11-SuperAKAP-IS (Arg11-QIEYVAKQIVDYAIHQA) and Arg11-
scrambled SuperAKAP-IS (Arg11-QDVEIHVKAAYYQQIAI) were synthe-
sized and puriﬁed to N90% purity (GenWay Biotech).2.3. Preparation of adult rat ventricular ﬁbroblasts
AVFswere isolated from10-week-oldmale Sprague–Dawley rats. Brief-
ly animals were euthanized in a preﬁlled CO2 chamber with 100% concen-
tration of CO2, and excised hearts were washed in ice-cold 1× ADS buffer
(116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4, 5.5 mM D-glucose,
5.4 mM KCl, 0.8 mMMgSO4). Ventricular tissues were minced into small
pieces and incubated overnight in a solution of 0.5 mg/ml trypsin (USB)
at 4 °C on an orbital shaker at 80 rpm. Trypsinized tissues subsequently
underwent four cycles of enzymatic digestion for 7 min at 37 °C in a solu-
tion of 80 mg/ml of type II collagenase (Worthington). Cells were pelleted
by centrifugation (800 rpm, 10 min) and resuspended in DMEM supple-
mentedwith 10% FBS and penicillin/streptomycin (Gibco). The resuspend-
ed cells were then passed through a 70 μm-cell strainer, seeded onto
uncoated plastic dishes and incubated for 2 h at 37 °C with 10% CO2.
DMEMwas subsequently replaced with EGM-2 to maintain cardiac ﬁbro-
blasts in an undifferentiated state [17]. Differentiation of AVFs to
AVMyoFs was induced by culturing cells in DMEM supplemented with
10% FBS and penicillin/streptomycin. Purity of AVFs and AVMyoFs prep-
arationswas determined by immunoﬂuorescence staining usingmouse
monoclonal anti-α-actinin (Sigma, 1:500 dilution), rabbit polyclonal
anti-desmin (Cell Signaling, 1:25 dilution) and mouse monoclonal
cy3-conjugated anti-vimentin antibodies (Sigma, dilution = 1:250).
The presence of contaminant endothelial cells was assessed by incubat-
ing primary cultures for 4 h in the presence of Dil-acyl LDL (Biomedical
Technologies Inc., dilution = 1:20). Cultures contained almost exclu-
sively primary ventricular ﬁbroblasts, as N95% of the cells were positive
for theﬁbroblastmarker vimentin,were negative for the cardiomyocyte
marker α-actinin and the vascular smooth-muscle cell marker desmin,
and were not labeled with Dil-acyl LDL (see Fig. S1A–D, in Supplemen-
tary material). Neonatal rat cardiomyocytes were used as a positive
control for α-actinin and desmin staining and as a negative control
for vimentin staining. The endothelial EA.hy 926 cell line was used as
a positive control for Dil-acyl LDL labeling. Western blot analysis of
AVF lysates conﬁrmed the presence of vimentin but not α-actinin
and desmin (see Fig. S1E–G, in Supplementary material). AVMyoF
transdifferentiation was assessed by staining cells using mouse mono-
clonal anti-α-SMA antibodies (Sigma, dilution = 1:500) (see Fig. S1H,
in Supplementary material).
2.4. Cell culture and treatment
Rat AVFs or AVMyoFs were seeded on 6-cm uncoated plastic dishes
at 6 × 105 cells per dish for Rhotekin pulldown experiments, Western
blots and real time PCR experiments. For indirect immunoﬂuorescence
experiments, ventricular ﬁbroblasts were seeded on 4.2 cm2 TPX Lab-
Tek chamber slides at 5 × 104 cells per chamber. For [3H]-proline incor-
poration assays, AVFs were seeded on uncoated 25-mm wells at
3 × 105 cells per well. When indicated, cells were treated with losartan
(1 μM; Sigma), SB203580 (10 μM; Calbiochem), PD123319 (1 μM;
Sigma), BMS-345541 (5 μM; Sigma), RO318220 (10 μM; Sigma),
Gö6976 (0.5 μM; Sigma), or Na3V04 (1 mM; Sigma) 6 h prior stimula-
tion with Ang II (100 nM; Sigma).
2.5. Production of lentiviruses
VSV-G pseudotyped lentiviruses were produced by cotransfecting
293-T cells with 20 μg of the pAB286.1 vectors encoding either the
AKAP-Lbc shRNAs, the Gα12 G228A dominant negative mutant, or
the Flag-RhoA N19 construct, 15 μg of pCMVDR8.91, and 5 μg of
pMD2.VSVG using the calcium phosphate method. Culture medium
was replaced by serum-freeDMEMat 12 h after transfection. Cell super-
natants were collected 48 h later, ﬁltered through a 0.22-μm ﬁlter unit
and concentrated using Centricon-Plus-70 MW 100,000 columns
(Millipore). Virus titers were determined by infecting HEK293 cells
using serial dilutions of the viral stocks and by scoring puromycin-
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method were between 1 × 108 and 8 × 108 TU/ml.
2.6. Lentiviral infection
AVFs or AVMyoFs were infected 24 h after plating using pAB286.1-
based lentiviruses encoding wild type or mutated AKAP-Lbc shRNAs,
theGα12 G228Amutant or the Flag-RhoAN19 construct at amultiplicity
of infection (MOI) of 50 in EGM-2 or DMEM supplemented with 10%
FBS, containing 8 μg/ml of polybrene. 48 h after infection, culture
media were replaced and ﬁbroblasts incubated for ﬁve additional days
in EGM-2 or DMEM supplemented with 10% FBS.
For rescue experiments, AVFswere transfected 4 days after infection
with the cDNA encoding human AKAP-Lbc-GFP or the AKAP-Lbc
Y2153F-GFP mutant using Lipofectamine 2000. Transfection was per-
formed in EGM-2 or DMEM in the absence of antibiotics for a period
of 6 h. 20 h after transfection, cells were serum starved for 24 h and
stimulated with 10−7 M Ang II for an additional 24 h. Pools of 104 GFP
positive (i.e. expressing AKAP-Lbc-GFP constructs) or GFP negative (i.e.
non-transfected) cells were sorted by FACS and used for quantitative
PCR experiments (see below).
2.7. Expression and puriﬁcation of recombinant proteins in bacteria
GST-tagged fusion proteins of the Rho-binding domain (RBD) of
Rhotekin were expressed using the bacterial expression vector
pGEX4T1 in the Bl21DE3 strain of Escherichia coli and puriﬁed. To induce
the expression of fusion proteins, exponentially growing bacterial cul-
tures were incubated for 24 h at 16 °C with 1 mM isopropyl 1-thio-β-
D-galactopyranoside (IPTG), and subsequently subjected to centrifuga-
tion. Pelleted bacteria were lysed in buffer A (50 mM Tris, pH 7.4,
500 mM NaCl, 10 mM MgCl2, 1% (w/v) Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 4 μg/ml leupeptin, 2 μg/ml aprotinin, 2 μg/ml
pepstatin, 0.1 mM phenylmethylsulfonyl ﬂuoride), sonicated, and cen-
trifuged at 34,000 ×g for 30 min at 4 °C. After incubating the superna-
tants with glutathione sepharose beads (Amersham Biosciences) for
1 h at 4 °C, the resin was washed ﬁve times with 10 volumes of buffer
A. The protein content of the beads was assessed by Coomassie Blue
staining of SDS-polyacrylamide gels. Beads were used immediately for
the Rhotekin RBD pulldown assay.
2.8. Rhotekin Rho-binding domain (RBD) pulldown assay
Infected rat AVFs or AVMyoFs grown for 6 days in EGM-2mediumor
in DMEM supplemented with 10% FBS were starved for 24 h in the ab-
sence of serum. Cells were then incubated for 15 min with or without
10−7 M Ang II and lysed in RBD lysis buffer (20 mM Tris, pH 7.4,
150 mM NaCl, 30 mM MgCl2, 1 mM dithiothreitol, 0.5% (w/v) Triton
X-100, 4 μg/ml leupeptin, 2 μg/ml aprotinin, 2 μg/ml pepstatin,
0.1 mMphenylmethylsulfonyl ﬂuoride). Lysates were subjected to cen-
trifugation at 20,600 ×g for 10 min at 4 °C and incubated with 30 μg of
RDB beads for 1 h at 4 °C. Beads were then washed three times with
RBD buffer, resuspended in SDS-PAGE sample buffer (100 mM Tris,
pH6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol), and analyzed by
SDS-PAGE.
2.9. Immunoprecipitation experiments
For immunoprecipitation of endogenous AKAP-Lbc, rat AVFs grown
in 100 mm dishes were lysed in 1 ml of buffer B (20 mM Tris pH7.4,
150 mM NaCl, 1% (w/v) Triton-X-100, 0.1% sodium deoxycholate,
5 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF). Cell lysates
were incubated for 4 h at 4 °C on a rotating wheel. The solubilized ma-
terial was centrifuged at 34,000 ×g for 30 min at 4 °C and the superna-
tants were dialysed overnight against buffer C (20 mM Tris pH 7.4,
150 mM NaCl, 1% (w/v) Triton-X-100, 5 μg/ml aprotinin, 10 μg/mlleupeptin and 1 mM PMSF). 2 mg of dialysed lysates were then in-
cubated for 4 h at 4 °C with 4 μg of rabbit polyclonal anti-AKAP-Lbc
antibodies (Covance) and 20 μl of Protein-A-sepharose beads to immu-
noprecipitate endogenous AKAP-Lbc proteins. Following a brief centri-
fugation on a bench-top centrifuge, the pelleted beads were washed
ﬁve times with buffer C and twice with PBS and proteins were eluted
in SDS-PAGE sample buffer by boiling samples for 3 min at 95 °C. For
immunoprecipitation of Flag-RhoA N19, rat AVFs infected with lentivi-
ruses encoding for the Flag-RhoA N19 mutant were lysed 7 days
after infection in 1 ml of buffer D (20 mM Tris, pH 7.4, 150 mM NaCl,
1% (w/v) Triton X-100, 4 μg/ml leupeptin, 2 μg/ml aprotinin, 2 μg/ml
pepstatin, 0.1 mM phenylmethylsulfonyl ﬂuoride). Cell lysates were in-
cubated for 1 h at 4 °C on a rotatingwheel. The solubilizedmaterial was
centrifuged at 34,000 ×g for 30 min at 4 °C, and the supernatants were
incubated for 4 h at 4 °C with 20 μl of anti-Flag M2 afﬁnity resin
(Sigma). Following a brief centrifugation on a bench-top centrifuge,
the pelleted beads were washed ﬁve times with buffer D and proteins
were eluted in SDS-PAGE sample buffer by boiling samples for 5 min
at 95 °C. Eluted proteins were analyzed by SDS-PAGE and Western
blotting.
2.10. SDS-PAGE and Western blotting
Samples denatured in SDS-PAGE sample buffer were separated on
acrylamide gels and electroblotted onto nitrocellulose membranes.
The blots were incubated with primary antibodies and horseradish-
conjugated secondary antibodies (Amersham Biosciences) as previous-
ly indicated [29]. The following afﬁnity-puriﬁed primary antibodies
were used for immunoblotting: mouse monoclonal anti-RhoA (Santa
Cruz, 1:250 dilution), mouse monoclonal anti-α-SMA (Sigma, 1:2000
dilution), rabbit polyclonal anti-Gα12 (Santa Cruz, 1:250 dilution),
mouse monoclonal anti-actin (Sigma, 1:2000 dilution), mouse
monoclonal anti-Flag (Sigma, 1:2000 dilution), mouse monoclonal
anti-α-actinin (Sigma, 1:500 dilution), rabbit polyclonal anti-desmin
(Cell Signaling, 1:1000 dilution), and mouse monoclonal anti-
vimentin (Santa Cruz, 1:200). Antibodies to AKAP-Lbc were generated
in rabbits using a KLH conjugated peptide (residues 2671–2694) as
the immunogen (Covance). AKAP-Lbc serumwas used at a 1:2000 dilu-
tion for immunoblots.
2.11. RNA extraction and real-time RT-PCR
Total mRNA was extracted from rat AVFs or AVMyoFs using the
RNeasy Fibrous Tissue Mini Kit (Qiagen) and single-strand cDNA was
synthesized from 0.05 μg to 0.5 μg of total RNA using random hexamers
(Applied Biosystems) and SuperScript II reverse transcriptase
(Invitrogen). Real-time PCRwas performedusing theApplied Biosystems
7500 Fast Real-Time PCR Systemwith TGF-beta1 (Rn01475963_m1),
α-SMA (Rn01759928_g1), and AKAP13 (Rn01478247_m1) Taqman
Gene expression Assays. β2-Microglobulin (Rn00560865_m1) mRNA
was used as invariant internal control.
2.12. Immunocytochemistry
Infected AVFs and AVMyoFs were grown for 5 days in EGM-2 medi-
um, serum starved for an additional 24 h and ﬁnally incubated for 24 h
with orwithout 10−7 MAng-II. Cells were thenwashed twicewith PBS,
ﬁxed for 10 min in PBS/3.7% formaldehyde, permeabilized for 5 min
with 0.5% (w/v) Triton X-100 in PBS, and blocked for 1 h in PBS/
1%BSA. The expression ofα-SMAwas assessed by incubating ﬁbroblasts
for 1 h with 1:500 dilution of the mouse anti-α-SMA monoclonal anti-
body (Sigma) followed by 1 h incubation with 1:250 dilution of Alexa
Fluor 488-conjugated anti-mouse secondary antibodies (Molecular
Probes). Immunoﬂuorescent staining was visualized using a Zeiss
Axiophot ﬂuorescence microscope.
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Fig. 1. AKAP-Lbc mediates Ang II-induced activation of RhoA in adult ventricular ﬁbro-
blasts. A) Real time quantitative PCR analysis of AKAP-Lbc expression in rat NVMs and
AVFs. B) Western blot analysis of AKAP-Lbc expression in lysates from rat AVFs and
AVMyoFs. C) Rat AVFs were infected with control lentiviruses or with lentiviruses
encoding wild type or mutated AKAP-Lbc shRNAs at a MOI of 50. Six days after infection
cells were incubated for 15 minwith or without 10−7 M Ang II. Cell lysates were incubat-
edwith GST-RBD beads. The bound RhoAwas detected using amonoclonal anti-RhoA an-
tibody (panel 1). The relative amounts of total RhoA (panel 2), AKAP-Lbc (panel 3) and
actin (panel 4) in the cell lysates were detected using speciﬁc antibodies, as indicated.
D)Quantitative analysis of theGTP-RhoA associatedwith RBDbeadswas obtained byden-
sitometry. The amount of RhoA bound to RBD (panel 1) was normalized to the RhoA con-
tent of cell extracts (panel 2). Results are expressed as mean ± S.E. of 3 independent
experiments. *P b 0.05 as compared with Rho-GTP levels measured in Ang II-stimulated
rat AVFs infected with mutated shRNAs.
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Infected AVFs were grown for 5 days in EGM-2 medium and for an
additional 24 h in the absence of serum. Cells were then incubated for
24 h with ascorbic acid (50 μg/ml), [3H]-proline (5 μCi/ml) and with
or without 10−7 M Ang II. Collagen secretion was then measured as
previously described [18].
2.14. Invasion and migration assays
Invasion assays were performed using a modiﬁed Boyden chamber
technique that measures the ability of adult rat ventricular ﬁbro-
blasts to migrate across a matrix barrier in response to Ang II. We
used 24-well tissue culture plates with inserts containing an 8 μm
pore-size polycarbonate membrane coated with Matrigel basement
membrane matrix (BD Biosciences). Rat AVMyoFs were quiesced in
DMEM containing 0.6% FCS for 24 h. Cells were then trypsinized, resus-
pended in DMEM containing 0.6% FCS and counted. 5 × 104 cells were
loaded into the upper chamber. The lower chamber was ﬁlled with
DMEM supplementedwith 0.6% FCS and 10−7 M Ang II. After a 24-h in-
cubation period, the cell suspension was aspirated, and the membranes
were ﬁxed in 70% ethanol at−20 °C for 30 min. Cells that had attached
but not migrated were removed, the membranes were rinsed in water,
and migrated cells on the underside of the membrane were visualized
with staining in 2% crystal violet. Cells were counted in 10 random ﬁelds
with a light microscope. Migration assays were performed as for inva-
sion assays, except that 104 cells were loaded on the top of uncoated
membranes (i.e. noMatrigel) and that the incubation period in the pres-
ence of Ang II was of 8 h.
2.15. Statistical analysis
Data are presented as means ± SE. All statistical analyses were per-
formed using one-way ANOVA with Tukey's multiple comparison tests.
3. Results
3.1. AKAP-Lbc is involved in angiotensin II-mediated RhoA activation in rat
AVFs
Among the proﬁbrotic factors that are secreted in the myocardium
in response to stress, Ang II has been shown to play a major role in me-
diating the cellular responses that ultimately lead to cardiac ﬁbrosis
[19–22]. While the implication of Rho GTPases in the pro-ﬁbrotic path-
ways activated by Ang II is well established [12], the identity of the Rho-
GEFs mediating these pathological responses in cardiac ﬁbroblasts has
remained elusive. In this context, we recently found that the RhoA-
speciﬁc GEF AKAP-Lbc is highly enriched in cardiac tissues where it
plays a key role in modulating the response of cardiomyocytes to stress
[14,15]. We now show, both by real time quantitative PCR and by
Western blot, that AKAP-Lbc is expressed in primary cultures of rat
AVFs and AVMyoFs (Fig. 1A and B) thus raising the possibility that it
might participate in the transduction of signals that initiate cardiac
ﬁbrosis.
To address this question, we initially assessed the impact of
inhibiting AKAP-Lbc expression by RNA interference on the ability of
Ang II to induce RhoA activation in rat AVFs. Short hairpin (sh) RNAs
speciﬁc to AKAP-Lbc or control shRNAs were delivered into rat AVFs
using lentiviral vectors. Gene silencing was conﬁrmed upon immuno-
blot analysis of cell lysates using AKAP-Lbc speciﬁc antibodies (Fig. 1C,
panel 3). RhoA activation was assessed using the Rhotekin pulldown
assay on cells treated for 15 minwith10−7 MAng II based on the obser-
vation that RhoA activation peaked at this time point (see Fig. S2, upper
panel, in Supplementary material). Interestingly, infection of rat AVFs
with lentiviruses encoding AKAP-Lbc speciﬁc shRNAs caused a near
complete inhibition of the ability of Ang II to induce the formation ofactive GTP-bound RhoA as compared to cells infected with control len-
tiviruses or lentiviruses expressing the mutated AKAP-Lbc shRNA
(Fig. 1C, panel 1, and D). This suggests that AKAP-Lbc plays a central
role in mediating the effects of Ang II on RhoA activation in ventricular
ﬁbroblasts.
Evidence accumulated over the last few years indicates that AKAP-
Lbc can anchor multiple signaling enzymes including kinases such
as PKA, PKC, PKD, MAP kinases and IKKβ, and tyrosine phosphatases
such as Shp2 that could potentially modulate RhoA signaling
[14,16,23–27]. This raises the possibility that the inhibitory effect of
AKAP-Lbc silencing on Ang-II-mediated RhoA activation (Fig. 1C)
could reﬂect the unhooking of these transduction enzymes from the
RhoA pathway.
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of type II PKA anchoring in adult ﬁbroblasts affected RhoA activity.
Treatment of rat AVFs with cell permeable type II PKA anchoring inhib-
itory peptides (SuperAKAP-IS) or control scrambled peptides (scram-
bled SuperAKAP-IS) [28] did not inﬂuence the formation of RhoA-GTP
induced by Ang II (see Fig. S3A, upper panel, lanes 2 and 4, and B, in Sup-
plementary material). However, in line with previous evidence indicat-
ing that anchored PKA inhibits the basal Rho-GEF activity of AKAP-Lbc
[29,30], inhibition of type II PKA anchoring signiﬁcantly enhanced
basal RhoA activation (see Fig. S3A, upper panel, lanes 1 and 3, and B).
Additional control experiments revealed that inhibition of p38,
MEK1, PKC, PKD, IKKβ, and tyrosine phosphatases using the inhibitors,
SB203580 and PD098059, RO318220, Gö6976, BMS-345541 and sodi-
um orthovanadate (Na3VO4), respectively, did not affect in a signiﬁcant
manner Ang II-mediated RhoA-GTP formation (see Fig. S3C, upper
panel, and D, in Supplementary material). These ﬁndings indicate that
the kinases and phosphatases anchored by AKAP-Lbc do not modulate
the effects of Ang II on RhoA signaling in rat AVFs.
Based on these ﬁndings, we undertook experiments aimed at deter-
mining the molecular players linking Ang II to the activation of AKAP-
Lbc–RhoA signaling pathway in AVFs. Ventricular ﬁbroblasts express
two different receptors for Ang II, namely AT1 receptors and AT2 recep-
tors [31]. To assess which of these receptor subtypes promotes RhoA ac-
tivation, rat AVFs were incubated with 1 μM losartan, an AT1 receptors
antagonist, or 1 μM PD123319, an AT2 receptors antagonist, prior Ang II
stimulation. RhoA-GTP formation was totally blocked by pre-treatment
with losartan but was not with PD123319 (see Fig. S4A, upper panel,
and B, in Supplementary material), suggesting that AT1 receptors are
the main receptor subtype mediating RhoA activation in rat AVFs.2 3 41
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Fig. 2. Gα12 mediates Ang II-induced AKAP-Lbc activation in adult ventricular ﬁbroblasts. A) R
mutant at a MOI of 50. Six days after infection cells were incubated for 15 min with or witho
bound RhoA (top) and the relative amounts of total RhoA (middle) and Gα12 G228A (bottom)
analysis of theGTP-RhoA associatedwith RBDbeadswas obtained bydensitometry as indicated
compared with Rho-GTP levels measured in Ang II-stimulated AVFs infected with control lenti
without Ang II at 10−7 M for 15 min. Cell lysates were subjected to immunoprecipitation (IP)
tracts were revealed using antibodies against RhoA (panels 1 and 2) and AKAP-Lbc (panel 3).
obtained by densitometry. Results are expressed as mean ± S.E. of 3 different experiments.
treated control rat AVFs. E) Rat AVFs were infected with control lentiviruses or lentiviruses enc
for 24 hwith orwithout 10−7 M Ang II and cell lysates were subjected to immunoprecipitation
extracts were revealed using speciﬁc antibodies, as indicated. F) Quantitative analysis of the am
are expressed as mean ± S.E. of 4 different experiments. *P b 0.05 as compared with levels of
lentiviruses.Based on our previous ﬁndings showing that AKAP-Lbc is a Gα12-
activated Rho-GEF [14], we then decided to assess the contribution of
Gα12 in mediating the activation of the AKAP-Lbc–RhoA pathway
downstream the AT1 receptors. To address this issue, rat AVFs were in-
fected with lentiviruses encoding a dominant negative mutant of Gα12
(Gα12 G228A) prior to stimulation with 10−7 M Ang II. We observed
that overexpression of the Gα12 G228Amutant inhibits by 77% the acti-
vation of RhoA induced by Ang II (Fig. 2A and B), suggesting that, in rat
AVFs, AT1 receptors mediate RhoA activation via Gα12.
In order to provide direct evidence that Ang II induces AKAP-Lbc ac-
tivation via AT1 receptors and Gα12, we determined whether losartan
treatment and expression of the Gα12 G228A mutant could impair the
interaction between endogenous AKAP-Lbc and RhoA in rat AVFs. Im-
portantly, we have previously shown that the formation of AKAP-Lbc–
RhoA complexes reﬂects the activation state of AKAP-Lbc [32]. Rat
AVFs were incubated with 1 μM losartan (Fig. 2C and D) or infected
with lentiviruses encoding for the Gα12 G228A mutant (Fig. 2E and F)
prior to stimulation with 10−7 M Ang II. Endogenous AKAP-Lbc was
then immunoprecipitated using anti-AKAP-Lbc antibodies and the pres-
ence of associated RhoA determined by immunoblot. Stimulation of
cellswithAng II induced a signiﬁcant increase in the amount of RhoA as-
sociated with AKAP-Lbc (Fig. 2C and E, upper panel, lane 2). This effect
was completely abolished by losartan treatment (Fig. 2C, upper panel,
lane 4; and D) and signiﬁcantly impaired following the expression of
the Gα12 G228A mutant (Fig. 2E, panel 1, lane 4; and F), indicating
that Ang II induces AKAP-Lbc activation via AT1 receptors and Gα12.
Collectively, these ﬁndings strongly suggest that, in adult ventricular
ﬁbroblasts, Gα12 and AKAP-Lbc control RhoA activation downstream of
AT1 receptors.E
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in Fig. 1D. Results are expressed asmean ± S.E. of 7 independent experiments. *P b 0.05 as
viruses. C) Rat AVFs pre-treated or not with 1 μM losartan 6 h prior to incubation with or
using anti-AKAP-Lbc antibodies. Western blots of the immunoprecipitates and the cell ex-
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*P b 0.05 as compared with levels of co-immunoprecipitated RhoA measured in Ang II-
oding the Gα12 G228Amutant at a MOI of 50. Six days after infection, cells were incubated
(IP) using anti-AKAP-Lbc antibodies.Western blots of the immunoprecipitates and the cell
ount of RhoA immunoprecipitated with AKAP-Lbc was obtained by densitometry. Results
co-immunoprecipitated RhoA measured in Ang II-treated rat AVFs infected with control
340 S. Cavin et al. / Biochimica et Biophysica Acta 1843 (2014) 335–3453.2. AKAP-Lbc controls α-SMA expression and associated phenotypic
conversion of cardiac ﬁbroblasts to myoﬁbroblasts
Myoﬁbroblast formation is a process crucially involved in thepathol-
ogy of cardiac ﬁbrosis. Recent evidence indicates that RhoA can regulate
myoﬁbroblast differentiation by promoting the nuclear translocation of
the serum response factor (SRF) and myocardin related transcription
factors (MRTFs), which, in turn, enhance transcription and expression
of smooth muscle speciﬁc genes such as α-SMA [8,10]. Based on these
ﬁndings and our current results identifying AKAP-Lbc as the mediator
of Ang II-induced RhoA activation in ventricular ﬁbroblasts, we investi-
gated the possibility that this anchoring protein could control α-SMA
expression and differentiation of cardiac ﬁbroblasts to myoﬁbroblasts.
To address this question, we initially determined whether silencing
the expression of AKAP-Lbc could affect Ang II-mediated induction of
the myoﬁbroblast marker α-SMA. Treatment of rat AVFs infected
with control lentiviruses or lentiviruses encoding mutated AKAP-Lbc
shRNAswith 10−7 M of Ang II for 24 h induced a 2.4 to 2.6 fold increase
in α-SMA expression as assessed by immunoblot (Fig. 3A, upper panel,
lanes 2 and 8, and B) and by real-time PCR (Fig. 3C). Interestingly, the
stimulatory effect of Ang II on the expression ofα-SMAmRNAs andpro-
teins was impaired by more than 90% in rat AVFs expressing AKAP-Lbc
shRNAs (Fig. 3A, lanes 4 and 6, B and C).
To provide a formal demonstration that the effects of AKAP-Lbc and
α-SMA expression are mediated by RhoA we performed experiments
that combined silencing of the endogenous anchoring protein and res-
cue with human AKAP-Lbc forms that are refractory to the rat-speciﬁc
shRNA (Fig. 3D). Rat AVFs were infected with lentiviruses encodingC
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encoding GFP fusion proteins of AKAP-Lbc or the AKAP-Lbc Y2153Fmu-
tant that lacks Rho GEF activity [14]. GFP negative (i.e. silenced cells)
and GFP positive cells (i.e. cells rescued using AKAP-Lbc GFP constructs)
were sorted by FACS and α-SMA expression determined by real-time
PCR. Our results indicate that rescue with wild type AKAP-Lbc fully re-
stored Ang II-mediated transcription of α-SMA, whereas rescue with
the AKAP-Lbc Y2153F mutant did not (Fig. 3D). Collectively, these ﬁnd-
ings indicate that the AKAP-Lbc–RhoA pathway plays a crucial role in
mediating the effects of Ang II on cardiac myoﬁbroblast differentiation.
A similar inhibition of Ang II-induced α-SMA expression was ob-
served following incubation of rat AVFs with the AT1R inhibitor losartan
(see Fig. S5A, upper panel lane 4, in Supplementary material) but not
with AT2R inhibitor PD123319 (see Fig. S5A, upper panel, lane 6, in Sup-
plementary material). Importantly, the effects of AT1Rs on cardiac
myoﬁbroblast differentiation were shown to require Gα12 and RhoA
since infection of rat AVFs with lentiviruses expressing dominant nega-
tive mutants of Gα12 (G228A) or RhoA (Flag-RhoA N19) signiﬁcantly
decreased Ang-II-induced α-SMA expression (see Fig. S5B, upper
panel, lanes 4 and 6, in Supplementary material).
To conﬁrm the implication of AKAP-Lbc in the process of cardiac
myoﬁbroblast formation induced by Ang II, we determined the impact
of AKAP-Lbc silencing on the ability of Ang II to promote morphological
changes and cytoskeletal reorganization in rat AVFs by immunoﬂuores-
cence microscopy. Treatment of rat AVFs infected with control lentivi-
ruses with Ang II for 24 h induced the assembly of α-SMA positive
stress ﬁber characteristic of myoﬁbroblasts (Fig. 4A and B) in about
54% to 58% of the cells. Ang II treated cells were also larger with a0
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341S. Cavin et al. / Biochimica et Biophysica Acta 1843 (2014) 335–345more rigid appearance. AKAP-Lbc silencing abolished Ang II-induced
α-SMA upregulation aswell asmorphological changes and cytoskeletal
reorganization (Figs. 4A and 2B). Silencing efﬁciency was evaluated by
immunoblot using anti-AKAP-Lbc antibodies (Fig. 4C). Taken together,
these results suggest that the Gα12–AKAP-Lbc–RhoA pathway controls
α-SMA expression and the phenotypic transition of cardiac ﬁbroblasts
to myoﬁbroblasts.
3.3. AKAP-Lbc mediates Ang II-induced collagen synthesis in rat AVFs
Based on the above results and knowing that cardiacmyoﬁbroblasts
produce and secrete excessive amounts of collagen-rich extracellular
matrix that contribute to cardiac ﬁbrosis and dysfunction [1], we deter-
mined the impact of AKAP-Lbc silencing on the ability of Ang II to pro-
mote ECM production in rat AVFs by assaying collagenase-sensitive
[3H]-proline incorporation. Incubation of rat AVFs infected with control
lentiviruses or lentiviruses encoding mutated AKAP-Lbc shRNAs with
10−7 M Ang II increased collagenase-sensitive [3H]-proline incorpora-
tion by 2.1 to 2.3 fold compared to untreated cells (Fig. 5A). This effect
was impaired by about 90% following the suppression of AKAP-Lbc ex-
pression (Fig. 5A). AKAP-Lbc silencing expressionwas conﬁrmed by im-
munoblot (Fig. 5B). These ﬁndings support the idea that AKAP-Lbc
mediates the upregulation of collagen production in cardiac ﬁbroblasts
in response to Ang II stimulation.
3.4. AKAP-Lbc mediates Ang II-induced TGF-β1 expression in rat AVFs
Strong evidence supports the notion that Ang II, through the stimu-
lation of AT1Rs, enhances the secretion of proﬁbrotic ligands such asTGF-β from activated cardiac ﬁbroblasts [1,6]. This favors the ampliﬁca-
tion of the ﬁbrotic response. Based on this observation, we determined
whether inhibition of AKAP-Lbc expression in rat AVFs could affect Ang
II-induced TGF-β1 expression as assessed by real time quantitative PCR.
We observed that Ang II treatment of control AVFs for 6 h with 10−7 M
Ang II increases TGF-β1 mRNA expression by around 2.1 fold (Fig. 6A).
Infection of rat AVFswith lentiviruses encoding AKAP-Lbc shRNAs total-
ly inhibited the ability of 10−7 M Ang II to induce TGF-β1 expression as
compared to cells infected with control lentiviruses or lentiviruses
encoding mutated AKAP-Lbc shRNAs (Fig. 6A). Importantly, rescue
with wild type AKAP-Lbc fully restored Ang II-mediated transcription
of α-SMA in silenced cells, whereas rescue with the AKAP-Lbc Y2153F
mutant did not (Fig. 6B). Collectively, these results further conﬁrm the
implication of the AKAP-Lbc–RhoA pathway in the ﬁbrotic response in-
duced by Ang II in primary cardiac ﬁbroblasts.3.5. Silencing of AKAP-Lbc expression impairs Ang II-induced myoﬁbroblast
migration and invasion
Differentiated cardiac myoﬁbroblasts display increased migratory
properties, which enhance their ability to invade the myocardium.
Previous studies suggested that myoﬁbroblast migration relies on the
activity of Rho-GTPases, which, by regulating remodeling of the cell cy-
toskeleton, control cell movement [11]. Our ﬁndings showing that
AKAP-Lbc mediates Ang II-induced RhoA activation in both rat AVFs
(Fig. 1C and D) and AVMyoFs (see Fig. S6A, upper panel, lanes 4 and 6,
in Supplementarymaterial) prompted us to investigate the possible im-
plication of this anchoring protein in cardiac myoﬁbroblast migration.
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AKAP-Lbc silencing could affect Ang II-induced AVMyoF migration.
Myoﬁbroblasts infected with control lentiviruses, or lentiviruses
encodingAKAP-Lbc shRNAs or the Flag-taggedRhoAT19Ndominant neg-
ative mutant were seeded on transwell membranes with 8 μm pores.
After a 24 h incubation period with Ang II at 10−7 M, the number of mi-
grated cells on the underside of themembranewas counted. As shown in
Fig. 7A and B, stimulation of AVMyoFs infected with control lentiviruses
with Ang-II increased their migratory capacity by 4.5 fold compared to
untreated cells. The stimulatory effect of Ang II was impaired by 50% to
67% following AKAP-Lbc silencing and by 88% following RhoA inhibition
(Fig. 7A and B). This suggests that the AKAP-Lbc–RhoA pathway contrib-
utes to the migratory response of myoﬁbroblasts to Ang II.
Based on these results, we determined whether AKAP-Lbc silencing
could also inﬂuence the invasive properties of cardiac myoﬁbroblasts.
To address this aspect, we assessed the ability of AVMyoFs to migrate
through a Matrigel basement membrane barrier in response to Ang II.
Our results indicate that AKAP-Lbc silencing reduces AVMyoF inva-
sion by 55% to 62% compared to cells infected with control lentiviruses
or lentiviruses encoding mutated AKAP-Lbc shRNAs (Fig. 7C and D).
Collectively, these ﬁndings suggest that the AKAP-Lbc–RhoA pathway
plays a prominent role in mediating the effects of Ang II on cardiac
myoﬁbroblast migration and invasion.
4. Discussion
While the implication of Rho signaling in cardiac ﬁbrosis has been
suggested by several recent studies [7,9,12,13], the molecular mecha-
nisms that promote Rho activation during this pathological cardiac
event are yet to be identiﬁed.
Our current results demonstrate that the Rho-speciﬁc exchange fac-
tor AKAP-Lbc is crucially involved in the transduction of pro-ﬁbrotic sig-
nals induced by Ang II in cardiac ﬁbroblasts. We initially provided
evidence that AKAP-Lbc mediates the effects of Ang II on RhoAactivation in rat AVFs. Ang II promotes activation of the AKAP-Lbc/
RhoA complex through a signaling pathway that requires the AT1R
and theα subunit of the heterotrimeric G protein G12. Importantly, sup-
pression of AKAP-Lbc expression inhibits the ability of Ang II to stimu-
late multiple pro-ﬁbrotic responses including the expression of the
proﬁbrotic factor TGF-β1, expression of α-SMA positive stress ﬁbers (a
response that is indicative of the differentiation of quiescent cardiac ﬁ-
broblast into myoﬁbroblasts), collagen production and myoﬁbroblast
migration. Based on these results, we propose a model in which activa-
tion of the Gα12–AKAP-Lbc–RhoA pathway downstream of AT1Rs par-
ticipates in the process of myoﬁbroblast differentiation and favors
associated enhancement of collagen synthesis and cell migration
(Fig. 8). Collectively, these ﬁndings identify AKAP-Lbc as a key regulator
of pro-ﬁbrotic responses in adult cardiac ﬁbroblasts.
Our previous ﬁndings indicate that, in cardiomyocytes, α1-ARs pro-
mote cardiomyocyte hypertrophy by stimulating the Rho-GEF activity
of AKAP-Lbc through Gα12 [15]. We now show that the Gα12–AKAP-
Lbc–RhoA transduction pathway is also mobilized by Ang II in cardiac
ﬁbroblasts to modulate pro-ﬁbrotic responses. This implies that Gα12-
coupled receptors can activate this conservedAKAP-Lbc-based signaling
module to promote pathophysiological responses in both cardiac
myocytes and ﬁbroblasts.
One intriguing observation is that the contribution of AKAP-Lbc to
the activation of RhoA induced by Ang II appears to be inﬂuenced by
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343S. Cavin et al. / Biochimica et Biophysica Acta 1843 (2014) 335–345the differentiation state of cardiac ﬁbroblasts (Figs. 1 and S4A). In fact,
our results indicate that silencing of AKAP-Lbc expression reduces the
ability of Ang II to activate RhoA to a greater extent in cardiac ﬁbroblasts
compared to myoﬁbroblasts (100% vs. 51% of inhibition). This raises the
possibility that, following differentiation, AKAP-Lbc might regulate
RhoA activation in concert with other Rho-GEFs. Possible candidates
might include Gα12/13 activated Rho-GEFs such as p115-Rho-GEF,PDZ-Rho-GEF or LARG, which have been previously shown to mediate
various cellular responses to Ang II [33–36].
Our current results provide evidence that AKAP-Lbc controlsα-SMA
expression and stressﬁber formation associatedwith the process of car-
diacmyoﬁbroblast differentiation (Figs. 3 and 4). Given the nearly com-
plete inhibition of α-SMA expression observed in AKAP-Lbc silenced
ﬁbroblasts, one could suggest that this anchoring protein represents
Gα12
AT1R
AKAP-Lbc
α-SMA expression
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Fig. 8.Model showing the role of AKAP-Lbc in the regulation of pro-ﬁbrotic responses in
ventricular ﬁbroblasts. The Rho-GEF activity of AKAP-Lbc is induced in response to Ang
II stimulation through a Gα12-mediated signaling pathway. GTP-bound Rho is released
from AKAP-Lbc and interacts with downstream effectors to induce α-SMA expression
and associated differentiation of quiescent cardiac ﬁbroblasts to myoﬁbroblasts, collagen
production, TGF-β1 transcription, and myoﬁbroblast migration.
344 S. Cavin et al. / Biochimica et Biophysica Acta 1843 (2014) 335–345the main Rho-GEF participating in the process of cardiac ﬁbroblast dif-
ferentiation induced by Ang II. The fact that expression of the AKAP-
Lbc Y2153F mutant in silenced AVFs is able to rescue the stimulatory
effects of Ang II on α-SMA expression (Fig. 3D) strongly suggests that
RhoA acts downstream of AKAP-Lbc to promote cardiac myoﬁbroblast
differentiation. A RhoA dependent signaling pathway controlling
α-SMA gene transcription has been recently identiﬁed in cardiac ﬁbro-
blasts and involves actin polymerization and subsequent nuclear local-
ization of the transcription factors MRTF-A and SRF, which can directly
bind the promoter region of theα-SMA gene [8,9]. Another potential al-
ternative effector cascade linking the AKAP-Lbc and RhoA to the tran-
scription of the α-SMA gene is represented by the p38 signaling
pathway, which can be selectively activated the AKAP-Lbc complex
[25] and which has recently been shown to mediate several pro-
ﬁbrotic responses induced by Ang II [37,38].
Interestingly, recent studies indicate that the RhoA speciﬁc exchange
factor GEFH1/Lfcmediatesα-SMA expression in retinal pigment epithe-
lial cells to promote retinal ﬁbrosis [39]. While these ﬁndings conﬁrm
the notion that RhoA-activating proteins act as key upstream regulators
of α-SMA expression, they also suggest that different Rho-GEFs can be
mobilized in different cell types to promote α-SMA expression,
myoﬁbroblast differentiation and associated ﬁbrosis.
Differentiated cardiac myoﬁbroblasts secrete higher amounts of
ECM that contribute to cardiac diastolic dysfunction. Previous evidence
indicates that inhibition of Rho signaling strongly attenuates interstitial
collagen I deposition in the myocardium of mice submitted to pressure
overload [40]. We now show, that silencing of the RhoA selective GEF
AKAP-Lbc regulates collagen production in adult cardiac ﬁbroblasts
(Fig. 5) suggesting a crucial role for AKAP-Lbc–RhoApathway in the reg-
ulation of ECM synthesis. Interestingly, additional evidence suggeststhat RhoA can regulate collagen I promoter activity through the activa-
tion of Smad proteins [41], thus providing a link between RhoA activa-
tion and collagen synthesis.
Cardiac myoﬁbroblasts display increased migratory and invasive
properties, which allow them to reach the sites of injury to promote
wound healing and adaptive remodeling [1]. In this respect, previous
evidence indicates that RhoA can promote cardiac ﬁbroblast invasion
by regulating cell migration as well as the expression and secretion of
thematrixmetalloproteinase 9 (MMP9) [11], a gelatinase that degrades
the basement membrane matrix. Our current results indicate that
AKAP-Lbc silencing reduces myoﬁbroblast migration and invasion
(Fig. 7)without affectingMMP9 expression (see Fig. S6C, in Supplemen-
tary material). These ﬁndings are consistent with the idea that inhibi-
tion of myoﬁbroblast migration following AKAP-Lbc silencing can
negatively impact the ability of myoﬁbroblasts to invade the ECM.
In conclusion, based on our current ﬁndings highlighting the role of
AKAP-Lbc as a key modulator of proﬁbrotic responses in cardiac ﬁbro-
blasts and on previous evidence demonstrating a role for AKAP-Lbc in
cardiomyocyte hypertrophy [15,16,26,42,43] it emerges that targeting
the AKAP-Lbc and its ability to bind and activate RhoA could represent
a potential strategy for reducing myocardial remodeling in response to
cardiac stress.
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